IVERIC bio, Inc. (Nasdaq: ISEE) announced today that it has entered into a term loan debt financing facility with Hercules Capital, Inc. (NYSE: HTGC) and Silicon Valley Bank providing the Company with total borrowing capacity of up to $250 million in non-dilutive debt financing.

Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs. The Company is committed to having a positive impact on patients’ lives by delivering high-quality, safe and effective treatments designed to address debilitating retinal diseases including earlier stages of age-related macular degeneration. For more information on the Company, please visit www.ivericbio.com.

https://ivericbio.com/

Therapeutics

Iveric Bio Announces Agreement For Up To $250 Million In Non-Dilutive Debt Financing With Hercules Capital And Silicon Valley Bank

Description

Company Information

Iveric Bio Announces Agreement For Up To $250 Million In Non-Dilutive Debt Financing With Hercules Capital And Silicon Valley Bank

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Company Information